Literature DB >> 17309661

Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia.

T Karl1, L Duffy, A Scimone, R P Harvey, P R Schofield.   

Abstract

Human genetic studies have shown that neuregulin 1 (NRG1) is a potential susceptibility gene for schizophrenia. Nrg1 influences various neurodevelopmental processes, which are potentially related to schizophrenia. The neurodevelopmental theory of schizophrenia suggests that interactions between genetic and environmental factors are responsible for biochemical alterations leading to schizophrenia. To investigate these interactions and to match experimental design with the pathophysiology of schizophrenia, we applied a comprehensive behavioural phenotyping strategy for motor activity, exploration and anxiety in a heterozygous Nrg1 transmembrane domain mutant mouse model (Nrg1 HET) using different housing conditions and age groups. We observed a locomotion- and exploration-related hyperactive phenotype in Nrg1 HETs. Increased age had a locomotion- and exploration-inhibiting effect, which was significantly attenuated in mutant mice. Environmental enrichment (EE) had a stimulating influence on locomotion and exploration. The impact of EE was more pronounced in Nrg1 hypomorphs. Our study also showed a moderate task-specific anxiolytic-like phenotype for Nrg1 HETs, which was influenced by external factors. The behavioural phenotype detected in heterozygous Nrg1 mutant mice is not specific to schizophrenia per se, but the increased sensitivity of mutant mice to exogenous factors is consistent with the pathophysiology of schizophrenia and the neurodevelopmental theory. Our findings reinforce the importance of carefully controlling experimental designs for external factors and of comprehensive, integrative phenotyping strategies. Thus, Nrg1 HETs may, in combination with other genetic and drug models, help to clarify pathophysiological mechanisms behind schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17309661     DOI: 10.1111/j.1601-183X.2006.00298.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  54 in total

Review 1.  Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.

Authors:  Christina Wilson; Alvin V Terry
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-07

2.  mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.

Authors:  Martin Engel; Peta Snikeris; Natalie Matosin; Kelly Anne Newell; Xu-Feng Huang; Elisabeth Frank
Journal:  Psychopharmacology (Berl)       Date:  2016-02-10       Impact factor: 4.530

3.  Disruption of the neuregulin 1 gene in the rat alters HPA axis activity and behavioral responses to environmental stimuli.

Authors:  S B Taylor; A R Taylor; J A Markham; A M Geurts; B Z Kanaskie; J I Koenig
Journal:  Physiol Behav       Date:  2010-11-16

4.  Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components.

Authors:  Ying-Jiun J Chen; Madeleine A Johnson; Michael D Lieberman; Rose E Goodchild; Scott Schobel; Nicole Lewandowski; Gorazd Rosoklija; Ruei-Che Liu; Jay A Gingrich; Scott Small; Holly Moore; Andrew J Dwork; David A Talmage; Lorna W Role
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

Review 5.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

6.  Enriched environment prevents cognitive and motor deficits associated with postnatal MK-801 treatment.

Authors:  Masoumeh Nozari; Mohammad Shabani; Mahdieh Hadadi; Nafiseh Atapour
Journal:  Psychopharmacology (Berl)       Date:  2014-04-26       Impact factor: 4.530

7.  The involvement of Type II Neuregulin-1 in rat visuospatial learning and memory.

Authors:  Adam R Taylor; Sara B Taylor; James I Koenig
Journal:  Neurosci Lett       Date:  2012-10-23       Impact factor: 3.046

Review 8.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 9.  Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases.

Authors:  Lin Mei; Klaus-Armin Nave
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

Review 10.  Role of cannabis and endocannabinoids in the genesis of schizophrenia.

Authors:  Emilio Fernandez-Espejo; Maria-Paz Viveros; Luis Núñez; Bart A Ellenbroek; Fernando Rodriguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  2009-07-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.